期刊
CURRENT OPINION IN BIOMEDICAL ENGINEERING
卷 7, 期 -, 页码 1-8出版社
ELSEVIER
DOI: 10.1016/j.cobme.2018.08.001
关键词
DNA barcoded nanoparticle; Nanotechnology; Drug delivery; CRISPR; RNAi; RNA
资金
- Georgia Tech startup funds
- NIH [T32EB021962]
- Cystic Fibrosis Research Foundation [DAHLMA15XX0]
- Parkinson's Disease Foundation [PDF-JFA-1860]
- Bayer Hemophilia Awards Program (AGE DTD)
Nanoparticles improve drug efficacy by delivering drugs to sites of disease. To effectively deliver a drug in vivo, a nanoparticle must overcome physical and physiological hurdles that are not present in cell culture, yet in vitro screens are used to predict nanoparticle delivery in vivo. An ideal nanoparticle discovery pipeline would enable scientists to study thousands of nanoparticles in vivo. Here, we discuss technologies that enable high throughput in vivo screens, focusing on DNA barcoded nanoparticles.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据